Empirical antibiotic treatment with piperacillin-tazobactam in patients with microbiologically-documented biliary tract infections

World Journal of Gastroenterology

Volumn 10, Issue 15, 2004, Pages 2281-2283

  Bassotti, Gabrio ^a,b   Chistolini, Fabio ^a   Sietchiping Nzepa, Francis ^a   de Roberto, Giuseppe ^a   Morelli, Antonio ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PIPERACILLIN PLUS TAZOBACTAM;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BILIARY TRACT DISEASE; BILIARY TRACT INFECTION; CLINICAL ARTICLE; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DEATH; DEMOGRAPHY; DRUG EFFICACY; FEMALE; GRAM NEGATIVE BACTERIUM; HUMAN; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DOCUMENTATION; MONOTHERAPY;

EID: 4344708762     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v10.i15.2281     Document Type: Article

References (28)

1. Lea AS, Feliciano DV, Gentary DO. Intra-abdominal infections - an update. J Antimicrob Chemother 1982; 9(Suppl A): 107-113
2. Westphal JF, Brogard JM. Biliary tract infections. A guide to drug treatment. Drugs 1999; 57: 81-91
3. Leung JW, Ling TK, Chan RC, Cheung SW, Lai CW, Sung JJ, Chung SC, Cheng AF. Antibiotics, biliary sepsis, and bile duct stones. Gastrointest Endosc 1994; 40: 716-721
4. Carpenter HA. Bacterial and parasitic cholangitis. Mayo Clin Proc 1998; 73: 473-478
5. Brody LA, Brown KT, Getrajdman GI, Kannegieter LS, Brown AE, Fong Y, Blumgart LH. Clinical factors associated with positive bile cultures during primary percutaneous biliary drainage. J Vasc Interv Radiol 1998; 9: 572-578
6. Boey JH, Way LW. Acute cholangitis. Ann Surg 1980; 191: 264-270
7. Thompson JE, Tomkins RK, Longmire WP. Factors in management of acute cholangitis. Ann Surg 1982; 195: 137-145
8. Munro R, Sorrell TC. Biliary sepsis: reviewing treatment options. Drugs 1986; 31: 449-454
9. Chang WT, Lee KT, Wang SR, Chuang SC, Kuo KK, Chen JS, Sheen PC. Bacteriology and antimicrobial susceptibility in biliary tract disease: an audit of 10-year's experience. Kaohsiung J Med Sci 2002; 18: 221-228
10. Desai TK, Tsang TK. Aminoglycoside nephrotoxicity in obstructive jaundice. Am J Med 1988; 85: 47-50
11. Eliopoulos GM, Moellering RC. Azlocillin, mezlocillin and piperacilin: new broad spectrum penicillins. Ann Intern Med 1982; 97: 755-760
12. Muller EL, Pitt HA, Thompson JE, Doty JE, Mann LL, Manchester B. Antibiotics in infections of the biliary tract. Surg Gynecol Obstet 1987; 165: 285-292
13. Gerecht WB, Henry NK, Hoffman WW, Muller SM, LaRusso NF, Rosenblatt JE, Wilson WR. Prospective randomized comparison of mezlocillin therapy alone with combined ampicillin and gentamicin therapy for patients with cholangitis. Arch Intern Med 1989; 149: 1279-1284
14. Thompson JE, Pitt HA, Doty JE, Coleman J, Irving C. Broad spectrum penicillins as an adequate therapy for acute cholangitis. Surg Gynecol Obstet 1990; 171: 275-282
15. Levine JG, Botet J, Kurtz RC. Microbiological analysis of sepsis complicating non-surgical biliary drainage in malignant obstruction. Gastrointest Endosc 1990; 36: 364-368
16. Demediuk B, Speer AG, Hellyar A. Induced antibiotic resistant bacteria in cholangitis with biliary sepsis. Aust N Z J Surg 1996; 66: 778-780
17. Sörgel F, Kinzig M. Pharmacokinetic characteristics of piperacillin/tazobactam. Intensive Care Med 1994; 20: S14-S20
18. Westphal JF, Brogard JM, Caro-Sampara F, Adloff M, Blickle JF, Monteil H, Jehl F. Assessment of the biliary excretion of piperacillin-tazobactam in humans. Antimicrob Agents Chemother 1997; 41: 1636-1640
19. Chamberland S, L'Ecuyer J, Lessard C, Bernier M, Provencher P, Bergeron MG. Antibiotic susceptibility profiles of 941 gram-negative bacteria isolated from septicemic patients throughout Canada. Clin Infect Dis 1992; 15: 615-628
20. Del Favero A, Menichetti F, Martino P, Bucaneve G, Micozzi A, Gentile G, Furno P, Russo D, D'Antonio P, Ricci P, Martino B, Mandelli F. A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clin Infect Dis 2001; 33: 1295-1301
21. Westphal JF, Blicklé JF, Brogard JM. Management of biliary tract infections: potential role of quinolones. J Antimicrob Chemother 1991; 28: 486-490
22. Sung JJ, Lyon DJ, Suen R, Chung SC, Co AL, Cheng AF, Leung JW, Li AK. Intravenous ciprofloxacin as treatment for patients with acute suppurative cholangitis: a randomized, controlled clinical trial. J Antimicrob Chemother 1995; 35: 855-864
23. Karachalios GN, Nasiopoulou DD,Bourlinou PK, Reppa A. Treatment of acute biliary tract infections with ofloxacin: a randomized, controlled clinical trial. Int J Clin Pharmacol Ther 1996; 34: 555-557
24. Rerknimitr R, Fogel EL, Kalayci C, Esber E, Lehman GA, Sherman S. Microbiology of bile in patients with cholangitis or cholestasis with and without plastic biliary endoprosthesis. Gastrointest Endosc 2002; 56: 885-889
25. Cohn SM, Lipsett PA, Buchman TG, Cheadle WG, Milsom JW, O'Marro S, Yellin AE, Jungerwirth S, Rochefort EV, Haverstock DC, Kowalsky SF. Comparison of intravenous/oral ciprofloxacin plus metronidazole versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections. Ann Surg 2000; 232: 254-262
26. Dietrich ES, Schubert B, Ebner W, Daschner F. Cost efficacy of tazobactam/piperacillin versus imipenem/cilastatin in the treatment of intra-abdominal infection. Pharmacoeconamics 2001; 19: 79-94
27. Holzheimer RG, Dralle H. Antibiotic therapy in intra-abdominal infections - a review on randomised clinical trials. Eur J Med Res 2001; 30: 277-291
28. Connor MJ, Schwartz ML, McQuarrie DG, Sumer HW. Acute bacterial cholangitis: an analysis of clinical manifestations. Arch Surg 1982; 117: 437-444